On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.
What is the problem?
Due to their favourable physico-chemical properties, PFAS are valuable for countless applications and products – including in the pharmaceutical sector. On the other hand, they pose an enormous challenge to the environment and human health: PFAS are persistent and have been detected worldwide in soil, water, food, wildlife and humans. Given the extent of contamination and the limitations of technically complex and costly remediation, scientists and regulatory authorities regard preventing further environmental pollution – i.e. regulating PFAS at source – as the most sustainable option.
What solutions are being discussed?
Due to the vast number of PFAS, regulating each individual compound is not feasible. The EU Chemicals Strategy for Sustainability therefore proposes regulating PFAS as a group. The European Chemicals Agency is currently reviewing a draft restriction under the EU Regulation on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), which covers around 10,000 compounds.
This would, in principle, prohibit the manufacture, placing on the market and use of PFAS, but provides for transition periods and sector-specific exemptions for applications where no suitable alternatives are currently available.
What happens next?
The European Chemicals Agency is expected to submit its final opinion to the European Commission by the end of 2026. The European Parliament will examine the Commission’s draft restriction. The European Commission will then present a concrete regulatory proposal for further deliberation.
The EPRS briefing highlights the key conflict of objectives:
Reducing risks to the environment and health through far-reaching restrictions
Whilst safeguarding critical applications and taking strategic industrial sectors into account
Reference:
https://www.gmp-publishing.com/blog/eu-forever-chemicals-in-a-conflict-of-interests
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
A significant uptick in M&A activity in the biosimilars sector is being driven by FDA regulatory reforms, a maturing patent litigation framework and a looming patent cliff — $200 billion of branded products are facing patent expiration by 2030.
The Drewry World Container Index edged lower this week as falling Asia-Europe rates outweighed firmer pricing on the Transpacific, with carriers preparing another round of blank sailings ahead of China’s Golden Week holiday.
Diacetone Alcohol (DAA) is an aliphatic hydroxy ketone produced through the base-catalysed aldol addition of two acetone molecules. It contains both ketone and tertiary hydroxyl functionalities, offering excellent solvency and chemical reactivity.
As a high-boiling oxygenated solvent and valuable chemical intermediate, DAA finds broad application in paints and coatings, printing inks, adhesives, industrial cleaning, cosmetics, and textiles. It is also used as an intermediate in the production of mesityl oxide and MIBK. (4-methylpentan-2-one).